Introduction to which generation of targeted drugs Ametinib belongs to and its treatment characteristics

Almonertinib (Almonertinib) is a third-generation EGFRtyrosine kinase inhibitor (EGF R-TKI) is mainly used to treat patients with non-small cell lung cancer (NSCLC) who carry EGFR sensitive mutations and have developed drug resistance. As a third-generation targeted drug, ametinib is structurally designed to target T790M resistance mutation sites, which can effectively overcome the resistance problems of first- and second-generation EGFR-TKIs and improve the clinical benefit rate of patients.

Compared with the first and second generation EGFR-TKI, ametinib has higher selectivity and can selectively inhibit the mutant EGFR signaling pathway, while having a weak inhibitory effect on wild-type EGFR. This feature allows it to control tumor proliferation while reducing the risk of toxic side effects on normal tissues and improving patients' tolerance and quality of life.

Clinical data show that ametinib shows a higher objective response rate (ORR) and prolonged progression-free survival (PFS) in patients with T790M mutation-positive advanced non-small cell lung cancer. At the same time, it also has good penetration and efficacy in patients with central nervous system (CNS) metastases, enriching treatment options for patients with brain metastases.

In general, ametinib, as a third-generation EGFR targeted drug, has the advantages of highly effective inhibition of drug-resistant mutations, low wild-type side effects, and coverage of the central nervous system, making it an important treatment option for patients with EGFR T790M mutation-positive NSCLC patients. Its precise targeting properties and good tolerability enable it to show significant therapeutic value in clinical applications.

Reference materials:https://www.drugs.com/